Pancreatic Cancer Research

ResearcherMayo ClinicNo recent work listed

Alfredo Romano

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5100869369. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2015: 3 papers · 2016: 4 papers · 2017: none · 2018: 1 paper

Papers 8

  1. nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Co-author DOI 10.1111/ajco.12999↗
  2. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial. Last author DOI 10.1007/s12325-016-0327-4↗
  3. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.185↗
  4. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from… Co-author DOI 10.1186/s12885-016-2798-8↗
  5. Dose modification and efficacy of nab-paclitaxel plus gemcitabine vs. gemcitabine for patients with metastatic pancreatic cancer: phase III MPACT trial. Co-author DOI 10.21037/jgo.2016.01.03↗
  6. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. Co-author DOI 10.1093/jnci/dju413↗
  7. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis o… Co-author DOI 10.1158/1078-0432.ccr-14-3222↗
  8. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel D. Von Hoff · 5 shared papers, 2015–2016 · strength 0.23
  2. David Goldstein · 4 shared papers, 2015–2016 · strength 0.19
  3. Josep M. Tabernero · 4 shared papers, 2015–2016 · strength 0.18
  4. Werner Scheithauer · 3 shared papers, 2015–2016 · strength 0.14
  5. Marion Harris · 2 shared papers, 2016–2018 · strength 0.12
  6. Rosemary Young · 2 shared papers, 2015–2018 · strength 0.11
  7. Ramesh K. Ramanathan · 2 shared papers, 2015–2016 · strength 0.10
  8. Volker Kunzmann · 2 shared papers, 2015–2016 · strength 0.10
  9. Pascal R. Hammel · 2 shared papers, 2015–2016 · strength 0.10
  10. Elena Gabriela Chiorean · 2 shared papers, 2015–2016 · strength 0.09
  11. Marc F Botteman · 1 shared paper, 2018 · strength 0.07
  12. Michael Ståhl · 1 shared paper, 2016 · strength 0.07
  13. Arndt Vogel · 1 shared paper, 2016 · strength 0.07
  14. Mustapha Ali Tehfe · 1 shared paper, 2016 · strength 0.06
  15. Hagen Fritz Kennecke · 1 shared paper, 2016 · strength 0.06
  16. Malcolm J. Moore · 1 shared paper, 2016 · strength 0.05
  17. Teresa Mercade Macarulla · 1 shared paper, 2016 · strength 0.05
  18. Wen Wee Ma · 1 shared paper, 2016 · strength 0.05
  19. Michele Reni · 1 shared paper, 2016 · strength 0.05
  20. Vinod Ganju · 1 shared paper, 2015 · strength 0.04
  21. Jeffrey R. Infante · 1 shared paper, 2015 · strength 0.04
  22. Colin D. Weekes · 1 shared paper, 2015 · strength 0.04
  23. Sunil R. Hingorani · 1 shared paper, 2015 · strength 0.04
  24. Carlos Plaza · 1 shared paper, 2015 · strength 0.04
  25. Manuel M. Hidalgo · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.